Research and development on the safety of iPS cell-based medicines
First written in FY2017-Q1. 22 of 26 entries say "Restated". Latest entry: FY2026-H1.
No other company in this theme has enough history to compare yet.
- FY2026-H1RestatedAnnual report
「Our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application.」
We have reaffirmed our policy of using RNA reprogramming technology as the foundation for producing high-quality iPS cells suitable for clinical application. - FY2025-H1RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2024-Q3RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2024-Q2RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed the safety challenge in the clinical application of iPS cells and the response to it through RNA reprogramming technology. - FY2024-Q1RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed RNA reprogramming technology as the technological foundation for producing highly safe iPS cells for clinical application. - FY2023-Q3RestatedAnnual report
「Ensuring safety is a technical challenge in the clinical application of iPS cells. We have developed and own RNA reprogramming technology for producing high-quality iPS cells best suited to clinical application.」
We have reaffirmed RNA reprogramming technology as the technological foundation for producing highly safe iPS cells for clinical application. - FY2023-Q2RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2023-Q1RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2022-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing clinical-use iPS cells with reduced risks of genetic mutations, exogenous genes and residual viruses. - FY2022-Q1RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the technological foundation for producing highly safe clinical-use iPS cells. - FY2021RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and reducing the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the technological foundation for producing highly safe iPS cells for clinical application. - FY2021-Q3RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2021-Q2RestatedAnnual report
「The greatest technical challenge in applying iPS cells to medicine is ensuring safety. We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2021-Q1RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2020AdvancedAnnual report
「Our group has successfully produced highly safe clinical-use iPS cells using its proprietary third-generation RNA reprogramming technology, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
The successful production of clinical-use iPS cells using RNA reprogramming technology was explicitly stated, indicating that safety technology had progressed to the stage of practical service deployment. - FY2020-Q3RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. This constitutes our technological advantage in iPS cell-based regenerative medicine.」
We have reaffirmed RNA reprogramming technology as the foundation for reducing the risks of genetic mutations, exogenous genes and residual viruses, and for our technological advantage in iPS cell-based regenerative medicine. - FY2020-Q2RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. This constitutes our technological advantage in iPS cell-based regenerative medicine.」
We have reaffirmed RNA reprogramming technology as the foundation for ensuring the safety of iPS cells for clinical application and for our technological advantage in regenerative medicine. - FY2020-Q1RestatedAnnual report
「We have developed and own RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2019-Q3RestatedAnnual report
「Our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. Academic papers have also reported that the frequency of chromosomal abnormalities leading to genetic mutations is markedly lower than with other iPS cell production methods, and the technology can be described as the latest iPS cell production technology currently best suited to clinical use.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2019-Q2RestatedAnnual report
「Our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. Academic papers have also reported that the frequency of chromosomal abnormalities leading to genetic mutations is markedly lower than with other iPS cell production methods, and the technology can be described as the latest iPS cell production technology currently best suited to clinical use.」
We have reaffirmed RNA reprogramming technology as the foundation for producing highly safe iPS cells for clinical application. - FY2019-Q1AdvancedAnnual report
「A grant was approved by an organization under the U.K. Department for Business, Energy and Industrial Strategy for a project led by our consolidated subsidiary REPROCELL Europe. The project aims to establish manufacturing technology for safer iPS cells better suited to clinical application using our RNA reprogramming technology.」
The approval of a grant from a U.K.-related organization represents concrete progress toward establishing manufacturing technology for safe iPS cells suitable for clinical application using RNA reprogramming technology. - FY2018RestatedAnnual report
「Our group has developed and owns third-generation RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses.」
We have positioned third-generation RNA reprogramming technology as the foundation for addressing safety issues and reaffirmed our policy of advancing its clinical application. - FY2018-Q3RestatedAnnual report
「Our group has developed and owns third-generation RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. Academic papers have reported that the frequency of chromosomal abnormalities leading to genetic mutations is markedly lower than with other iPS cell production methods, and the technology can be described as the latest iPS cell production technology currently best suited to clinical use.」
We have reaffirmed that RNA reprogramming technology is designated as a third-generation technology, that academic papers report a markedly lower frequency of chromosomal abnormalities than with other production methods, and that it is suitable for clinical use. - FY2018-Q1RestatedAnnual report
「Our group has developed and owns RNA reprogramming technology for producing high-quality iPS cells suitable for clinical application, minimizing the risk of genetic mutations and eliminating the risk of residual exogenous genes or viruses. As a research support business, we have begun contract services for producing iPS cells using this technology. Going forward, our group will advance the clinical application of this technology and promote regenerative medicine using iPS cell technology.」
We have reaffirmed our policy of advancing contract services using RNA reprogramming technology and the clinical application of that technology. - FY2017AdvancedAnnual report
「As a result, we successfully developed a technology using RNA technology, a next-generation technology, that minimizes the risk of genetic mutations and enables the production of high-quality iPS cells without the risk of residual exogenous genes or viruses.」
The successful development of a technology for producing high-quality iPS cells using RNA technology was explicitly stated, indicating that safety technology for clinical application had progressed from the development stage to the stage of confirmed results. - FY2017-Q1First statedAnnual report
「We are actively conducting research and development on the safety of iPS cells, the most significant challenge in clinical applications, and possess highly competitive proprietary technologies, including RNA reprogramming technology and a technology for removing residual iPS cells jointly developed with SBI Pharmaceuticals Co., Ltd.」
Safety technology is the central research and development focus for the clinical application of iPS cell therapeutics.